相关实验视频
Updated: Feb 14, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
结肠炎相关的结肠直肠瘤在性结肠炎与原发性硬化结肠炎:一个全国性的研究
Koichi Komatsu1, Takahide Shinagawa1, Motoi Uchino2
1Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
患有性结肠炎 (UC) 和原发性硬化性胆道炎 (PSC) 的患者比没有PSC的患者更早,更年轻地发展出结肠直肠瘤 (UCAN). 在PSC-UCAN组中,早期癌症更常见,这表明早期监测有好处.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 在患有原发性硬化性胆道炎 (PSC) 的患者中,性结肠炎相关的结肠直肠瘤 (UCAN) 在日本尚未研究.
- 这项研究调查了UCAN在PSC和UC (PSC-UC) 患者中的临床病理特征和预后.
研究的目的:
- 为了比较患有和没有PSC的患者之间UCAN的临床病理特征和预后.
- 评估PSC对UCAN发展和特征的影响.
主要方法:
- 从1983年到2020年,对808名UCAN患者进行了回顾性分析.
- 分类为PSC-UCAN (n=26) 和UCAN-单独 (n=782) 组.
- 临床病理特征和10年总生存率 (OS) 和癌症特异性生存率 (CSS) 的比较.
主要成果:
- PSC-UCAN组的UC持续时间较短 (12.8岁与16.9岁),UCAN诊断时的年龄较小 (47.8岁与53.3岁).
- 在PSC-UCAN组中,UCAN在右侧结肠中发生的频率更高 (34.6%对15.9%).
- PSC-UCAN显示了较低的高度发育不良 (19.2%与30.7%) 和更多的早期癌症 (53.9%与31.2%) 的趋势. 操作系统和CSS是可以比较的.
结论:
- 与单独使用UCAN的患者相比,PSC-UCAN患者的UCAN发育更早,更年轻.
- 在PSC-UCAN组中观察到右侧结肠UCAN的高患病率和更频繁的早期癌症.
- 早期启动监测结肠镜检查可能对患有PSC-UC的患者有益.
更多相关视频
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
08:51Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
Published on: August 24, 2019
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...